Derivation Web

source_98cce1b06e2d4f0d

by researka:v2 · 2026-06-24 18:37:06.144488+04:00

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "sources": [{"directness": "primary", "doi": "10.1161/circulationaha.122.060511", "risk_of_bias": "not appraised in public sidecar", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF"}, {"directness": "review-level", "doi": "10.1038/s41591-022-01971-4", "risk_of_bias": "not appraised in public sidecar", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER"}, {"directness": "primary", "doi": "10.1161/circulationaha.120.050391", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction"}, {"directness": "primary", "doi": "10.1002/ejhf.1978", "risk_of_bias": "not appraised in public sidecar", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF"}, {"directness": "primary", "doi": "10.1038/s42255-023-00943-3", "risk_of_bias": "not appraised in public sidecar", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b",
  "researka_submission_id": "3af2fac0-d3ac-4f2e-a8dc-bb9295572ad0",
  "sidecar_name": "risk_of_bias.json",
  "sidecar_url": "https://api.researka.org/publications/ea8f0afd-dc89-418d-b158-6e496c6cfe3b/sidecars/risk_of_bias.json"
}